文献速递妇科

III期随机临床试验中子宫内膜癌术后辅助化疗后复发模式及危险因素分析

Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
PubMed 文献 · Gynecol Oncol · 2019-10-07

本研究分析JGOG2043随机III期试验中接受术后辅助化疗的子宫内膜癌患者,193例可分析患者中局部复发占50%、远处复发占63%。复发时CA125≥100 U/mL、远处转移、无病间期≤12个月及未行腹主动脉旁淋巴结清扫与较差的复发后总生存独立相关。

要点

  • 193例中局部复发50%、远处复发63%,远处复发累及腹腔者42%。
  • 复发后中位总生存23.9个月,CA125≥100 U/mL与远处转移独立相关于较差生存。
  • 无病间期≤12个月与未行腹主动脉旁淋巴结清扫亦独立相关于较差复发后生存。

核心结论

  • 子宫内膜癌辅助化疗后复发常发生在治疗后1年内,常见复发部位为腹腔和区域淋巴结。
  • 治疗相关因素中,复发后生存与无病间期和腹主动脉旁淋巴结清扫相关。

研究设计与样本

  • 随机III期试验JGOG2043纳入具有高进展风险的子宫内膜癌患者,分析其中复发患者的临床信息及复发相关因素与临床病理因素的相关性。
  • 共分析193例患者。

主要发现

  • 193例中局部复发占50%,远处复发占63%;局部复发累及区域淋巴结者占30%,远处复发累及腹腔者占42%。
  • 影像学确认复发者占83%,中位无病间期为11.5个月。
  • 与无病间期≤12个月显著相关的因素为手术残留肿瘤(p < 0.01)、组织学3级(p < 0.01)和淋巴结转移(p = 0.03);紫杉醇联合卡铂治疗与无病间期>12个月显著相关(p = 0.04)。
  • 复发后中位总生存为23.9个月;多因素分析中,复发前CA125≥100 U/mL(p < 0.01)、远处转移(p < 0.01)、无病间期≤12个月(p = 0.02)及未行腹主动脉旁淋巴结清扫(p = 0.01)与较差的复发后生存独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was to analyze patterns and risk factors of relapse after postoperative adjuvant chemotherapy for endometrial cancer. METHODS: Among patients enrolled in a randomized phase III trial (JGOG2043) investigating the efficacy of adjuvant chemotherapy for endometrial cancer at a high risk of progression, the recurrent patients were studied. Clinical information were collected, and correlation between relapse-related factors and clinicopathological factors were analyzed. RESULTS: Among 193 patients analyzed, 50% had local relapse and 63% had distant relapse. Local relapse involved regional lymph nodes in 30%, while distant relapse involved the abdominal cavity in 42%. Imaging was used to confirm relapse in 83%, and the median disease-free interval (DFI) was 11.5 months. Factors showing a significant correlation with DFI ≤12 months were residual tumor at surgery (p < 0.01), Grade 3 histology (p < 0.01), and lymph node metastasis (p = 0.03). In contrast, treatment with paclitaxel and carboplatin showed a significant correlation with DFI >12 months (p = 0.04). The median post-relapse overall survival (RS) was 23.9 months. In multivariate analysis, CA125 ≥ 100 U/mL prior to relapse (p < 0.01), distant metastasis (p < 0.01), DFI ≤ 12 months (p = 0.02), and not performing para-aortic lymphadenectomy (p = 0.01) were independently related to poor RS. CONCLUSIONS: Relapse of endometrial cancer following adjuvant chemotherapy often occurs by 1 year after treatment, with common relapse sites of the abdominal cavity and regional lymph nodes. Among treatment-related factors, RS was correlated with DFI and para-aortic lymphadenectomy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nomura H, Aoki D, Susumu N, et al. Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial. Gynecol Oncol. 2019. PMID: 31601493. doi:10.1016/j.ygyno.2019.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。